Baseline characteristics of the initial cohort
Group . | . | . | . | . | . |
---|---|---|---|---|---|
Health controls | ID | Sex | Age | ||
PB | PB1 | M | 28 | ||
PB2 | F | 25 | |||
PB3 | F | 41 | |||
PB4 | F | 71 | |||
PB5 | F | 62 | |||
PB6 | M | 33 | |||
PB7 | F | 26 | |||
PB8 | F | 27 | |||
PB9 | M | 26 | |||
PB10 | F | 58 | |||
PB11 | F | 56 | |||
PB12 | F | 28 | |||
PB13 | F | 31 | |||
PB14 | F | 26 | |||
BM | BM1 | F | 75 | ||
BM2 | F | 28 | |||
BM3 | M | 38 | |||
BM4 | M | 54 | |||
Acute leukemias | ID | Sex | Age | Blasts (BM) | |
ALL | ALL1 | M | 20 | 96 | |
ALL2 | M | 12 | 46 | ||
ALL3 | M | 1 | 93 | ||
ALL4 | F | 3 | 92 | ||
ALL5 | F | 19 | 99 | ||
AML | AML1 | M | 26 | 90 | |
AML2 | F | 90 | 90 | ||
AML3 | F | 64 | 80 | ||
AML4 | F | 84 | 31 | ||
AML5 | F | 56 | 90 | ||
AML6 | M | 23 | 30 | ||
AML7 | F | 58 | 80 | ||
AML8 | F | 1 | 72 | ||
AML9 | M | 74 | 87 | ||
AML10 | F | 72 | 90 | ||
AML11 | F | 55 | 95 | ||
AML12 | F | 36 | 93 | ||
AML13 | M | 75 | 33 | ||
AML14 | F | 51 | 75 | ||
AML15 | F | 45 | 77 | ||
AML16 | M | 65 | 46 | ||
AML17 | M | 52 | 90 | ||
TBD | ID | Sex | Age | Telomere length (percentile) | Germ line variant |
TBD | TBD1 | F | 20 | <1 | TINF2/p.R282C |
TBD2 | M | 10 | <10 | DKC1/p.A353V | |
TBD3 | F | 16 | <10 | TERT/p.R865H | |
TBD4 | M | 40 | <1 | Not identified | |
TBD5 | F | 35 | <1 | Not identified | |
TBD6 | F | 64 | <1 | Not identified | |
TBD7 | M | 57 | <10 | TERC/r.C94T | |
TBD8 | M | 59 | 30 | TERT/p.R865H | |
TBD9 | M | 27 | <1 | TERT/p.R865H |
Group . | . | . | . | . | . |
---|---|---|---|---|---|
Health controls | ID | Sex | Age | ||
PB | PB1 | M | 28 | ||
PB2 | F | 25 | |||
PB3 | F | 41 | |||
PB4 | F | 71 | |||
PB5 | F | 62 | |||
PB6 | M | 33 | |||
PB7 | F | 26 | |||
PB8 | F | 27 | |||
PB9 | M | 26 | |||
PB10 | F | 58 | |||
PB11 | F | 56 | |||
PB12 | F | 28 | |||
PB13 | F | 31 | |||
PB14 | F | 26 | |||
BM | BM1 | F | 75 | ||
BM2 | F | 28 | |||
BM3 | M | 38 | |||
BM4 | M | 54 | |||
Acute leukemias | ID | Sex | Age | Blasts (BM) | |
ALL | ALL1 | M | 20 | 96 | |
ALL2 | M | 12 | 46 | ||
ALL3 | M | 1 | 93 | ||
ALL4 | F | 3 | 92 | ||
ALL5 | F | 19 | 99 | ||
AML | AML1 | M | 26 | 90 | |
AML2 | F | 90 | 90 | ||
AML3 | F | 64 | 80 | ||
AML4 | F | 84 | 31 | ||
AML5 | F | 56 | 90 | ||
AML6 | M | 23 | 30 | ||
AML7 | F | 58 | 80 | ||
AML8 | F | 1 | 72 | ||
AML9 | M | 74 | 87 | ||
AML10 | F | 72 | 90 | ||
AML11 | F | 55 | 95 | ||
AML12 | F | 36 | 93 | ||
AML13 | M | 75 | 33 | ||
AML14 | F | 51 | 75 | ||
AML15 | F | 45 | 77 | ||
AML16 | M | 65 | 46 | ||
AML17 | M | 52 | 90 | ||
TBD | ID | Sex | Age | Telomere length (percentile) | Germ line variant |
TBD | TBD1 | F | 20 | <1 | TINF2/p.R282C |
TBD2 | M | 10 | <10 | DKC1/p.A353V | |
TBD3 | F | 16 | <10 | TERT/p.R865H | |
TBD4 | M | 40 | <1 | Not identified | |
TBD5 | F | 35 | <1 | Not identified | |
TBD6 | F | 64 | <1 | Not identified | |
TBD7 | M | 57 | <10 | TERC/r.C94T | |
TBD8 | M | 59 | 30 | TERT/p.R865H | |
TBD9 | M | 27 | <1 | TERT/p.R865H |
F, female; M, male.